title: [Infliximab-induced lupus erythematosus in a case of ulcerative colitis].
abstract: Infliximab is widely used in the treatment of inflammatory bowel disease, but despite its good clinical efficacy and tolerance, drug-induced autoimmune disorders have been reported as adverse reactions and are a matter of concern. Here we report a patient with ulcerative colitis who developed drug-induced lupus erythematosus after infliximab treatment. While this is a rare complication of infliximab, early diagnosis and successful management are essential.
authors: Department of Gastroenterology and Hematology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama.
authors: Jun
authors: J
authors: Nishikawa
authors: Takako
authors: T
authors: Miyazaki
authors: Nobuhiro
authors: N
authors: Suzuki
authors: Yuko
authors: Y
authors: Itaya
authors: Hidemoto
authors: H
authors: Yamawaki
authors: Hiroshi
authors: H
authors: Mihara
authors: Yushi
authors: Y
authors: Hasumoto
authors: Haruka
authors: H
authors: Fujinami
authors: Kohei
authors: K
authors: Ogawa
authors: Ayumu
authors: A
authors: Hosokawa
authors: Takahiko
authors: T
authors: Kudo
authors: Toshiro
authors: T
authors: Sugiyama
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab